Identifying biologic-eligible patients, Hurley Stage 2 or 3, in HS patients


Understanding the specific patient characteristics that show which HS patients are likely to respond to biologic therapy


  • Leverage OM1 linked, clinical EMR and claims data that includes Hurley stage, steroid dosing and exposure
  • OM1 data also includes extracted disease activity descriptors for body location and use of bDMARDs

Patients with clinical notes


With linked EMR and medical claims